Zenas’s autoimmune drug achieves main goal in late-stage trial
Zenas BioPharma (NASDAQ:ZBIO) reported positive late-stage clinical trial results for its experimental autoimmune therapy, hitting its primary and all key secondary targets in a study that could position the treatment as a new standard of care for a rare, debilitating inflammatory condition.










